The 2026 CMS Physician Fee Schedule introduces sweeping reforms to how skin substitutes—commonly referred to as cellular and tissue-based products (CTPs)—are reimbursed under Medicare Part B. These updates fundamentally change payment methodology, billing mechanics, and compliance expectations.
For providers, these changes are not incremental—they redefine financial viability, product strategy, and documentation standards in wound care.
This guide breaks down what changed, why it matters, and how to adapt.
A Shift to Flat-Rate Reimbursement
Beginning January 1, 2026, CMS established a uniform national payment rate of $127.14 per square centimeter for most skin substitutes that are not classified as biologics.
This represents a major departure from the previous Average Sales Price (ASP)-based reimbursement model, which allowed payments to fluctuate based on manufacturer pricing.
Key Implications:
Incident-To Supply Classification
Non-biologic CTPs (those without FDA Biologics License Application approval) are now treated as incident-to supplies when used in covered wound care procedures. In contrast, biologic products continue to be reimbursed using the Average Sales Price (ASP) methodology.
Separate Payment Structure
CMS now reimburses two distinct components for HOPD.
Billing Workflow by Setting
Facility (HOPD)
No Reimbursement for Wasted Product
One of the most operationally significant changes:
Even though wastage must still be documented, it has zero financial recovery .
Operational impact:
CMS implemented these reforms in response to explosive spending growth.
Drivers included:
CMS’ goal: control costs while maintaining access to effective therapies.
CMS is beginning to align reimbursement with FDA regulatory pathways.
Three categories now guide future policy direction:
CMS has signaled future plans to:
This could significantly reshape product competitiveness in the coming years.
Standard of Care
Before applying a skin substitute, providers must document:
Standard of care includes:
Failure is defined as:
Documentation Requirements
Providers must establish:
Documentation must be continuous and updated throughout treatment.
Application Limits
Medicare allows:
These limits remain unchanged under the new rule.
While most policies focus on:
Coverage for other wound types depends on:
CMS is introducing prior authorization through the WISeR (Wasteful and Inappropriate Service Reduction) Model.
This signals a broader trend toward:
Under a fixed reimbursement model:
Providers should prioritize:
With tighter reimbursement controls:
Success under the new model requires:
The 2026 CMS changes are complex and continue to evolve, with downstream impacts on clinical practice, reimbursement, and product strategy. At WoundGenex, we are committed to helping providers stay ahead of these shifts.
We will continue publishing deep dives on key topics—including billing nuances, documentation best practices, and regulatory updates, etc.
Be sure to check back regularly for new insights and practical guidance designed to help you navigate this changing landscape with confidence!